Dr. Buijs has over 3 decades’ experience in biotechnology with a focus on interaction analysis. He attained his PhD in Wageningen, the Netherlands, studying antibody interactions and continued as Post Doc at the University of Utah and research group leader at Uppsala University. In 2007, he was appointed as adjunct Professor in Biotechnology. He has been developing interactions analysis technology at Biacore (Cytiva) and was leading the design of the Biacore T200 and 8K systems. In 2013, he started as CTO at Ridgeview Instruments that provides LigandTracer instruments for interaction analysis on live cells. Currently, Jos is CEO and board member of Ridgeview Instruments AB and has an adjunct professor position at Uppsala University.

Hans Boumans is director technology transfer at TNO and as such responsible for some 40 TNO spin-off companies. In addition, he is a member of the supervisory board of 4 of these companies. He is also a board member of the pension fund of TNO and a board member of a European organization regarding technology transfer.

Hans has a scientific background, holds a PhD in biochemistry and molecular biology.

Dr. Jan Groen is the Chairman and Chief Executive Officer of Intravacc. He was previously the CEO of Novigenix (CH), a privately-owned immunotranscriptomic diagnostic company, and MDxHealth, a Public-listed genomic diagnostics company in the USA. His career spans many years in the global life science sector. He was the President and COO of Agendia (USA), co-founder of ViroClinics and DxOrange, and has held management and scientific positions at Focus Diagnostics (USA), the Erasmus Medical Center, the National Institute of Public Health, and Akzo-Nobel. Currently he is investment advisor at Oncode Institute, Chairman of the Board of Angle Plc. (UK), Board member of SPL Medical and Novigenix (CH). He has published over 125 papers in international scientific journals and holds a PhD in Medical Microbiology from Erasmus University Rotterdam.

Karel has 20+ years leadership experience from Life Science, Pharma and Diagnostics in multinational pharmaceutical-chemical companies. During 11 years in executive management and board positions as CEO of the Czech Merck subsidiary and later Head of EEMEA region in Merck Millipore division, Karel built up a broad international network of top level managers in Biotech, Pharma and Life Science industries.